Back to search results

Iscador® P (Mistletoe) Immunotherapy for Recurrent Resectable Osteogenic Sarcoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Osteogenic Sarcoma Recurrent

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Hackensack University Medical Center, Hackensack, New Jersey, United States

    Contact: Study coordinator (Laura Goode, MS, RN, PCNS-BC) · laura.goode@hmhn.org · 5519964995
    Contact: Principal Investigator (Katharine Offer, MD)

  • M.D. Anderson Children's Cancer Hospital, Houston, Texas, United States

    Contact: Study coordinator (Karen Moody, MD) · kmoody@mdanderson.org · 713-792-2260
    Contact: Principal Investigator (Karen Moody, MD)
Study leads

  • Katharine Offer, MD

    Principal Investigator

    Hackensack Meridian Health

  • Karen Moody, MD

    Principal Investigator

    MD Anderson

View source on ClinicalTrials.gov(opens in a new tab)